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The genetic engineering of vascular grafts offers
the promise of improved graft function and of sus-
tained intravascular delivery system of therapeutic
proteins. The purpose of this study was to genetical-
ly engineer a stent graft with a highly efficient vector
capable of inducing long-term stable gene expres-
sion in vascular tissue.
Central to the engineering process is the ability
to introduce the gene coding for a desired therapeu-
tic enzyme into a target cell safely and reliably. The
amphotrophic murine leukemia retroviral vector
(ampho–MuLV) has been successfully applied to
cells of vascular origin, albeit with a low gene trans-
fer efficiency. MuLV pseudotyped with the envelope
G glycoprotein from the vesicular stomatitis virus
(VSVG–MuLV) has shown significant improvement
in transduction efficiency and stability.1,2 The glyco-
protein is thought to interact with a phospholipid
component of the target cell membrane to mediate
viral entry via membrane fusion.3-5 This interaction
contrasts with the ampho–MuLV, whose entry
necessitates a specific receptor protein on the target
cell surface.6 The VSVG pseudotyped vector has
been successfully applied to human peripheral blood
lymphocytes,7,8 leukocytes,9 and hepatocytes.10 The
significant improvement in transduction efficiency of
this retroviral vector has not yet been fully explained
nor has been applied to vascular tissue.
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Purpose: The purpose of this study was first to compare the gene transfer efficiency of
amphotrophic murine leukemia viral vector (ampho–MuLV) with the efficiency of
MuLV pseudotyped with the vesicular stomatitis virus G glycoprotein (VSVG–MuLV)
in tissue of vascular origin. The second purpose of this study was to determine cell reten-
tion after the implantation of genetically engineered stent grafts.
Methods: Gene transfer efficiency was ascertained with the b -galactosidase assay. The tar-
get tissues included endothelial cells (ECs), smooth muscle cells (SMCs), and human
saphenous veins (HSVs). Polyurethane stent grafts were suffused with lac Z–transduced
ECs and SMCs that were harvested from porcine jugular vein. The grafts were implant-
ed into the iliac artery of each pig whose jugular vein had been harvested. Cell retention
was analyzed at 1 and 4 weeks with X-Gal staining.
Results: VSVG–MuLV transduction efficiency exceeded that of ampho–MuLV in human
ECs (VSVG–MuLV, n = 24, 89% ± 6%; ampho–MuLV, n = 18, 14% ± 6%; P < .001),
human SMCs (VSVG–MuLV, n = 5, 92% ± 3%; ampho–MuLV, n = 4, 17% ± 2%; P < .001),
pig ECs (VSVG–MuLV, n = 4, 81% ± 2%; ampho–MuLV, n = 4, 13% ± 3%; P < .001), and
pig SMCs (VSVG–MuLV, n = 5, 89% ± 3%; ampho–MuLV, n = 4, 16% ± 1%; P < .001).
As much as a 10-fold higher transduction efficiency was observed with VSVG–MuLV in
HSVs. After the stent graft implantation, the engineered cells were retained and prolifer-
ated on the stent membrane, with ingrowth into the underlying intima.
Conclusion: VSVG–MuLV significantly increased the gene transfer efficiency in vascular
SMCs and ECs and in organ-cultured HSVs. The cells were retained and proliferated on
stent grafts for the short term in the pig. (J Vasc Surg 1999;29:863-73.)
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MATERIALS AND METHODS
The gene transfer efficiency of the VSVG–MuLV
was evaluated in vascular endothelial cells (ECs) and
smooth muscle cells (SMCs). A similar evaluation
was performed in organ-cultured human saphenous
vein (HSV) segments. Stent grafts then were suf-
fused with these cells, and their survival was investi-
gated in vivo. The word suffusion signifies perme-
ation of the entire graft and coverage of both the
inner and the outer surfaces.
The protocol for the use of excreta human vein
was approved by the Institutional Review Board (no.
969-042). The animal protocol was approved by the
University of Southern California Animal Care
Committee.
Harvest and culture of enothelial cells and
smooth muscle cells. The cells were derived from
human and porcine tissue. The segments of HSV were
obtained from patients who underwent bypass graft-
ing surgery at the University of Southern California
hospitals. The porcine jugular veins were excised from
white pigs (25 kg) with general anesthesia.
The ECs and SMCs from both human and pig
were harvested and cultured similarly. The veins were
transported from the operating room to the laborato-
ry in RPMI 1640 media (Gibco BRL, Gaithersburg,
Md) that contained 20 mmol/L N-2-hydrox-
yethylpiperazine-N-2-ethanesulfonic acid, 2 mmol/L
L-glutamine, 50 U/mL penicillin, 50 m g/mL strep-
tomycin, 2.5 m /mL gentamicin, and 2.5 m g/mL
amphotericin B. Once in the laboratory, the veins
were flushed with RPMI media, clamped at one end,
filled with 0.1% collagenase I (Gibco BRL) in
Dulbecco’s phosphate-buffered saline solution (PBS),
and incubated for 10 minutes at 37˚C. The dissociat-
ed ECs were pelleted with centrifugation at room
temperature at 1200 rpm (200g) for 5 minutes. The
cells were resuspended in an EC medium and plated
onto 0.1% fibronectin precoated dishes. The EC
medium contained MCDB 131 medium (Gibco
BRL), 20% fetal bovine serum (FBS; Hyclone, Logan,
Utah), 50 m g/mL porcine intestinal mucosa-derived
heparin (Sigma, St Louis, Mo), 50 m g/mL EC
growth supplement (Becton Dickinson, Franklin
Lakes, NJ), 2 mmol/L L-glutamine (Gibco BRL),
and the antibiotics mentioned previously.
After EC dissociation, the SMCs were harvested.
The vein was incised longitudinally, and the intimal
layer was scraped off with a scalpel. The opened vein
was placed into tissue culture flasks and agitated in
Dulbecco’s PBS that contained collagenase I (1.8
mg/mL) and elastase (0.2 mg/mL) for 1 hour at
37˚C. Single-cell suspension supernatant was removed
and pelleted with centrifugation at 1200 rpm for 5
minutes. These SMCs were resuspended and cultured
in Williams’ medium (Gibco BRL) that contained 20%
FBS, L-glutamine (2 mmol/L), and the antibiotics
mentioned previously. All the cells were maintained in
a humidified 37˚C incubator with 5% CO2 and were
passed at a 1:5 ratio and used for experiments between
passages 2 through 10.
Confirmation of EC identity was on the basis of
cellular morphology, fluorescent staining for acety-
lated low-density lipoprotein uptake with Dil-A-C-
LDL11 (Biomedical Tech, Stoughton, Mass), and
immunohistochemical staining for von Willebrand
factor. The SMCs were identified with immunohis-
tochemical staining for smooth muscle a -actin. NIH
3T3 and 293T/17 cell lines (both from America
Type Culture Collection) were maintained in
Dulbecco’s modified Eagle’s medium (Gibco BRL)
that was supplemented with 10% FBS and 2
mmol/L glutamine.
Retroviral production and titer determination.
The replication-incompetent retroviral vectors
Ampho–MuLV and VSVG–MuLV, each bearing a b -
galactosidase reporter gene, were generated from a
transient three-plasmid transfection system.12 Briefly,
293T/17 cells (1 · 106 cells in a 100-mm diameter
dish) were transfected with calcium phosphate precip-
itation with the following three plasmids (10 m g each):
pCnBgSN, pHIT60, and pCVG for VSVG–MuLV or
pCAE for ampho–MuLV. Plasmid pCnBgSN13 is a
retroviral vector that contains a lac Z gene encoding
nuclear-localized b -galactosidase and a neomycin resis-
tance gene encoding for neomycin phosphotrans-
ferase. Plasmid pHIT60 is a Maloney MuLV Gag 
and Pol expressing plasmid.12 Plasmid pCVG is a
cytomegalovirus driven VSV-G expression vector.
Plasmid pCAE is a cytomegalovirus driven plasmid
expressing the amphotropic envelope from 4070A.14
Sixteen hours after transfection, the cells were cul-
tured with 10 mL of medium that contained 10
mmol/L sodium butyrate (Sigma) for 12 hours. The
culture then was replaced with 6 mL of fresh medium
to allow the production of retroviral vectors. The viral
supernatants were harvested after another 12 hours of
incubation at 37˚C, passed through a 0.4-m filter, and
titered with infection of NIH 3T3 cells. The viral
infectious titers were analyzed with both G418-resis-
tant colony formation and b -galactosidase activity
assay. NIH 3T3 cells were plated onto six-well plates
(2.5 · 104/well) the day before transduction. The
appropriate dilution of the viral supernatant (0.5 mL)
with 8 m g/mL hexadimethrine bromide (Sigma) was
added to each well and incubated for 2 hours, fol-
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lowed by the addition of 2 mL of fresh medium. After
an overnight culture, the medium was replaced with
fresh medium for either G418 selection or X-Gal stain-
ing. For G418 selection, the cells were cultured with
medium that contained 0.6 mg/mL G418 (Gibco
BRL) for 7 days and the resistant colonies were count-
ed after staining with 1% methylene blue (Sigma) in
methanol. For X-Gal staining, the cells were incubated
for another 48 hours before they were fixed with 0.5%
glutaraldehyde in PBS followed by three washes with
PBS for 10 minutes each time at room temperature.
The cells then were stained for b -galactosidase activity
with overnight incubation at 37˚C with a PBS solution
that contained 1 mg/mL X-Gal (Gibco BRL), 2
mmol/L MgCl2, 5 mmol/L K3Fe(CN)6, and 5
mmol/L K4Fe(CN)6. The clusters of blue cells 
were counted with an inverted microscope. The viral
titers that were analyzed with both methods were
found to be similar. The titers of VSVG–MuLV and
ampho–MuLV were 6 · 106, and 6 · 105 colony-
forming units/mL, respectively. In the transduction of
cells and veins, equal volumes of each virus super-
natant were applied unless specifically noted.
Transduction of endothelial cells and smooth
muscle cells. Transduction was performed with
100-mm plates in which EC or SMC proliferation
had reached approximately 50% confluence. The 
target ECs or SMCs were mixed with 2 mL of
ampho–MuLV or VSVG–MuLV viral supernatants
that contained 8 m g/mL polybrene at 37˚C for 2
hours, followed by the addition of 8 mL of fresh
medium and overnight culture. The multiplicities of
infection were 10 and 100, respectively. On day 2,
the cultures were changed into fresh media and the
cells were cultured for 2 days before being used for
graft suffusion or for transduction efficiency assay.
The transduction efficiency was analyzed with b -
galactosidase expression after the titer procedure
described previously. Transduction efficiency was
calculated with the ratio of the number of blue cells
(transduced) to the total number of cells that were
contained in 10 randomly picked, high-power fields
(100· ).
Transduction of human saphenous vein. The
veins were transported from the operating room to
the laboratory in the transport medium described
previously. Once in the laboratory, the veins were
flushed with RPMI media and the excess periadven-
titial tissue was removed. Rectangular (5 · 10 mm)
vein patches were pinned down with two 25-gauge
needles, with the luminal surface facing upwards, in a
60 · 20–mm petri dish with a 6-mm layer of Sylgard
184 resin cured (Dow Corning) in its base. A small
channel was cut out of the Sylgard to allow adequate
nutrition and to prevent tissue necrosis on the under-
surface. The plates were sterilized with ethylene
oxide gas before HSV culturing. Vein segments were
cultured for 14 days at 37˚C in a static environment
with 5% CO2. The vein organ culture medium was
Williams’ medium that was supplemented with 2
g/L sodium bicarbonate (Gibco/BRL), antibiotics
(as per transport solution), 2 mmol/L L-glutamine,
and 30% (vol/vol) FBS. The culture medium was
replaced every 2 days. Seven days after explantation,
the vein was mixed with 1 mL of ampho–MuLV or
VSVG–MuLV viral supernatants that contained 8
m g/mL polybrene and were cultured at 37˚C for 2
hours, followed by the addition of 3 mL of fresh
medium. One member of each pair of vein patches
was exposed to the ampho–MuLV supernatant,
whereas the other was exposed to the VSVG–MuLV
supernatant. The veins were cultured for 7 more days
and then fixed and stained for b -galactosidase expres-
sion as described above. En face analysis of the lumi-
nal surface of vein segments was performed with a
microscope at 200· magnification. The transduced
cells per high-power field were counted from seven
selected areas.
Cell suffusion onto the stent graft. The bal-
loon expandable stent grafts used were composed of
a metallic stent (length, 3 cm; outside diameter, 2
mm) wrapped with a thin polyurethane carbonate
membrane (Cordis–Johnson & Johnson, Warren,
NJ). A stent graft provides a minimally invasive alter-
native to bypass grafting surgery. It is deployed into
the circulation with catheter technology via a small
incision in a remote artery, typically the femoral
artery. The final deployment diameter depends on
the iliac diameter (6 mm in this study).
The stent grafts were pretreated with FBS for 2
hours. The cells were trypsinized from 100-mm tis-
sue culture plates and prepared to achieve a density
of 5 · 105 cells/mL. The graft was mixed with the
cell suspension in an Eppendorf tube and was incu-
bated while being rolled at 37˚C for 2 hours. At the
end of 2 hours, each stent graft was transferred to a
plate and cultured with media for 3 days. The suf-
fused grafts then were used for in vivo studies.
Deployment trauma. Cell retention on stent
grafts was determined after balloon expansion in
vitro. A stent graft uniformly suffused with cells was
split in half. One half was balloon expanded into a 6-
mm polytetrafluoroethylene (PTFE) graft with a 6-
mm balloon inflated to 10 atm for 10 seconds, and
then the balloon was deflated. The other half of the
stent graft was not expanded and served as a control.
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Both halves were trypsinized and the eluted cells
were counted in a hemocytometer. The experiment
was repeated once.
In vivo studies. Each pig (n = 6) from which the
external jugular vein was harvested for cell procure-
ment underwent anesthesia again for stent graft
implantation 10 to 14 days later. During this time,
ECs and SMCs were harvested and cultured,
VSVG–MuLV lac Z gene transfer was performed, and
the engineered cells were suffused onto the stent
grafts where they were allowed to proliferate. The
greatest variability in this process in regards to time
expended was observed in the cell harvest step as a
result of the variability in the number of cells obtained
from the jugular vein. Two to 6 days would elapse
until the disassociated cells grew to confluence.
The animals underwent anticoagulation therapy
with aspirin (325 mg) and warfarin sodium starting 3
days after surgery. At a 1 mg daily dose, the interna-
tional normalized ratio was 1.5 ± 0.5. Daily warfarin
sodium doses of 5 mg are lethal by 7 days.
Zolazepam and xylazine hydrochloride were used for
initial sedation. Buprenorphine was used for analge-
sia. Atropine was given before intubation. General
anesthesia was administered with isoflurane. Bilateral
femoral arteriotomies were performed. The femoral
artery was cannulated, and baseline angiography was
performed. The 3 cm–long stent graft suffused with
cells was placed onto a 4-cm balloon angioplasty
catheter (Cordis Inc, Miami, Fla). To avoid injury of
the cells with manual compression, the stent graft
was crimped onto the balloon with a silk suture
pulled tightly once at each end and once in the mid-
dle. The stent graft and catheter then were advanced
with fluoroscopic guidance into the iliac artery inside
a 10F sheath. The stent graft suffused with ECs was
placed in one iliac artery, and the graft suffused with
SMCs was placed in the contralateral iliac artery.
Buprenorphine by intramuscular injection was given
for postoperative analgesia. The pigs were maintained
for either 1 week (n = 5) or 1 month (n = 1).
The arteries with the stent grafts inside were
excised, flushed with PBS, fixed with 0.5% glutaralde-
hyde in PBS, and stained with X-gal as described previ-
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Fig 1. Transduction of endothelial cells (EC) and smooth muscle cells (SMC) with murine
leukemia viral vectors. Pig endothelial cells (a,c) and smooth muscle cells (b,d) were transduced
with amphotrophic murine leukemia viral vector (a,b) or murine leukemia viral vector pseudo-
typed with the vesicular stomatitis virus G glycoprotein (c,d). Both vectors bear lac Z gene encod-
ing for nuclear localized b -galactosidase. Three days after transduction, cells were stained with X-
gal for b -galactosidase activity. Cells with blue-stained nuclei represent cells successfully trans-
duced with viral vector, expressing b -galactosidase enzyme.
ously. Histopathology was performed with hema-
toxylin-eosin staining for cells, Masson trichrome stain-
ing for collagen, and Verhoeff’s staining for elastin.
Statistical analysis. Statistical comparisons
were performed with independent group t test for
unpaired observations. P values of less than .05 were
considered significant. Data are expressed as the
mean ± SD. An exception came in the analysis of
HSV in which a nonhomogeneous cell distribution
in a small population of samples prevented a precise
mean and SD from being derived. Not only was
there a gradient of cells transduced toward the cut
edges of the vein, there was also a gradient with
depth. A relative estimate was derived on the basis of
counts performed on high-power fields of maximal
cell population (ie, where the X-gal–stained blue
cells were the most dense).
RESULTS
High-efficiency gene transfer onto endothelial
cells and smooth muscle cells. Both ECs and
SMCs that were isolated from HSV and from porcine
jugular vein were transduced with VSVG–MuLV or
ampho–MuLV that carried lac Z genes (Fig 1).
Transduction efficiencies were found to be indepen-
dent of cell type (EC vs SMC) and organism (human
vs pig). The aggregate transduction efficiency of
VSVG–MuLV, which was 89% ± 6% (n = 38), signif-
icantly exceeded that of the ampho–MuLV vector,
which was 15% ± 5% (n = 30; P < .001). The com-
posite data are summarized in Table I.
Saphenous vein transduction in vitro. Excreta
HSV segments were cultured in a modified organ cul-
ture dish. Transduction of the cultured vein patches
with VSVG–MuLV or ampho–MuLV vectors bearing
lac Z gene is shown in Fig 2. Gene transfer was con-
centrated at the cut edges of HSV patches and was
also present on the intimal and adventitial surfaces of
the HSV patches. Surface en face analysis of five pairs
of transduced HSV showed as much as a 10-fold
higher transduction efficiency with VSVG–MuLV as
compared with Ampho–MuLV.
Suffusion of the modified cells on a stent
graft. With the highly efficient VSVG–MuLV
pseudotyped vector, the primary cultured ECs and
SMCs were transduced at a 90% efficiency. As such,
the transduced cells were used without needing to
undergo the selection process. The lac Z gene–trans-
duced cells were suffused onto polyurethane car-
bonate membrane–wrapped stent grafts. After 3 days
in culture, the grafts were stained with X-gal to
detect the cells grown on the graft (Fig 3). The cells
grew on both the metallic stent (Fig 3B) and the
polyurethane carbonate membrane (Fig 3C).
Cell retention after 7-day implantation period.
Stent grafts suffused with lac Z–transduced cells were
balloon expanded into the iliac arteries of the donor
pigs—one side with an EC–suffused stent graft and
the other with an SMC–suffused graft. We previously
determined in vitro that 30% to 50% of the cells are
lost during balloon deployment of the stent graft by
counting the number of cells trypsinized from the
stent grafts before and after ballon deployment.
Fortunately, a substantial number of suffused cells (2
to 3 · 105) did remain on the 3 cm–long stent graft
after the deployment procedure.
The stent grafts (n = 5) were recovered within 1
week after implantation, and the recovered grafts
were stained with X-Gal to analyze the retention of
the suffused cells. The engineered cells were present
on the stent membranes in vast quantities (Fig 4).
There were more cells on the membrane after
implantation (Fig 5B) than before implantation (Fig
5A), which indicated that the suffused cells prolifer-
ated in vivo. There was no significant difference in
cell retention between ECs and SMCs. There was
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Table I. Transduction efficiency of amphotrophic murine leukemia viral vectors and vesicular stomatitis virus
G glycoprotein–pseudotyped murine leukemia viral vectors in human and pig vascular cells 
Human Pig
EC SMC EC SMC
Mean (%) SD n Mean (%) SD n Mean (%) SD n Mean (%) SD n
Ampho 14 6 18 17 2 4 13 3 4 16 1 4
VSVG 89 6 24 92 3 5 81 2 4 89 3 5
EC, Endothelial cells; SMC, smooth muscle cells; n, number of experiments (not wells) representing data from cells obtained from dif-
ferent patients and pigs; Ampho, amphotrophic murine leukemia viral vector; VSVG, murine leukemia viral vector pseudotyped with the
vesicular stomatitis virus G glycoprotein.
one SMC–suffused stent graft in which the cells were
concentrated in a strip after exposure to blood flow
(Fig 5D), and the other stents displayed cells evenly
distributed similar to just before implantation.
The artery underlying each stent graft was
stained with X-gal to determine whether cells from
the stent graft grew into the underlying intima.
Positive b -galactosidase activity was found in each
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Fig 2. Transduction of cultured human saphenous veins, which were cultured for 7 days before
being mixed with amphotrophic murine leukemia viral vector (a,c) or with murine leukemia viral
vector pseudotyped with the vesicular stomatitis virus G glycoprotein (b,d) supernatants. X-gal
staining was performed 7 days after transduction. En face observation of transduced cells was per-
formed with microscopy, 100· (c,d). 
Fig 3. Growth of transduced endothelial cells on stent graft. Stent grafts were suffused with
endothelial cell that was transduced with murine leukemia viral vector pseudotyped with the vesic-
ular stomatitis virus G glycoprotein bearing lac Z gene (a). Graft was stained with X-gal for b -
galactosidase activity 3 days later. Metallic stent and polyurethane carbonate membrane were sep-
arated. Cellular growth on metallic stent (b) and polyurethane carbonate membrane (c) were
microscopically examined (100· ).
specimen (Fig 6A,B), which confirmed that the cells
suffused onto the stent graft had grown into the
underlying intima. This staining pattern was not
seen in neighboring normal (control) artery.
Graft implanted for 1 month. The suffused
cells were well retained on the graft but were 
covered by a neointima (Fig 7A). Immuno-
histochemical staining results of the neointima
cells were positive for a -actin, which indicated the
presence of SMCs. The neointima matrix had pos-
itive staining results for collagen and elastin.
DISCUSSION
Although gene transfer with an adenoviral vector
is highly efficient, the transferred gene is not incor-
porated into chromosomes and, accordingly, gene
expression is transient. On the other hand, retroviral
vectors derived from MuLV can achieve stable gene
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Fig 4. Cell retention on stent grafts 1 week after implantation. Stent graft was suffused with lac
Z–transduced endothelial cells (a,b) and then implanted into pig iliac arteries for 1 week. Grafts
were stained with X-gal for b -galactosidase activity. Graft membranes either before implantation
(a) or at 1 week after implantation (b) show blue color indicating retention of suffused cells.
Control (untransduced) cells did not show positive b -galactosidase activity (c).
Fig 5. Endothelial cell and smooth muscle cell retention on stent membrane. Polyurethane car-
bonate membranes stained with X-gal were examined with microscopy (100 · ). Transduced
endothelial cell (a,c) and smooth muscle cell (b,d) suffused stent membranes were examined
before (a,b) and after (c,d) implantation into pig iliac arteries for 1 week. 
transfer that results in long-term gene expression.
However, the efficiency of ampho–MuLV gene
transfer is low. Less than one of five cells will be trans-
duced after exposure to this retroviral vector. The
nontransduced cells need to be killed to yield a uni-
form cell population expressing the transferred gene.
To do this, the complexity of the gene construct is
increased by the addition of a toxin resistance gene
(and its promoter). A toxin, such as the neomycin
analog G418, is given to kill the untransduced cells.
Only the cells that are successfully transduced with
the gene of interest along with the neomycin resis-
tance gene survive. This process, known as selection,
could be avoided if the vector’s gene transfer effi-
ciency were closer to 100%. The ability to skip the
selection step is important for the following two rea-
sons: (1) the gene construct would be significantly
less complex, and (2) the 1-week to 2-week period
for the selection and repopulation of the surviving
cells in vitro would no longer be necessary.
In this study, we found that the VSVG–pseudo-
typed MuLV could efficiently transduce the reporter
gene lac Z at a 90% efficiency into both vascular ECs
and SMCs. This far exceeded the less than 20% effi-
ciency that was observed with the ampho–MuLV in
the same cell lines. Because most of the target cells
were transduced with VSVG–MuLV, the selection
step becomes less necessary.
When the VSVG–MuLV was diluted to the same
concentration of infective units (multiplicity of
infection) as ampho–MuLV, the EC transduction
efficiency was still four-fold higher. The higher
transduction efficiency seen in this study was thus
not solely a result of the 10-fold higher titer of the
VSVG–MuLV supernatant. In that study, we also
found that the expression of the transduced lac Z
gene was stable for more than a 35-day period (five
passages) and that pseudotransduction (protein
transfer) was not a cause for the highly efficient gene
transfer (to be published).
The next step in the development of a biological-
ly active graft is to find a suitable scaffold for the
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Fig 6. Growth of suffused cells into arterial wall. Iliac artery underlying the stent graft was recov-
ered together with the graft and stained with X-gal. On luminal surface en face, b -galactosidase
positive cells were observed (100· magnification) after artery was separated from graft. Examples
from two pigs are shown (a,b).
Fig 7. Stent graft after 1 month implantation. Stent graft
suffused with lac Z–transduced endothelial cells was
recovered after 1 month of implantation in pig iliac arter-
ies (a). Graft was cut open longitudinally and stained with
X-gal. There was a new layer of tissue on the luminal sur-
face of the stent graft (white arrow).
genetically engineered cells so that they may be
implanted in vivo. One possible scaffold could be an
autogenous conduit. In our first step in this direction,
we harvested HSV and applied the VSVG–MuLV
vector to it. There was a much higher expression of
the lac Z reporter gene as compared with the
ampho–MuLV. However, retroviral vectors necessi-
tate cell proliferation for gene transfer. Three to 4
days after a vessel is harvested and pinned down in
organ culture, cells are seen migrating from the cut
ends. A neointima begins to form. This is not a
desired characteristic in bypass grafting. In addition,
the protective endothelial cell layer of the intima is
altered. Whether these adverse consequences of organ
culture will be offset by the benefit of introducing a
gene into the conduit remains to be seen.
An alternative solution is to “grow a vessel” on a
scaffold in vitro. During the past decade, a variety of
approaches have been used to develop ways to
improve the patency rate of bypass grafting. Seeding
of endothelial cells on prosthetic grafts was used to
improve the patency rate of small diameter prosthet-
ic grafts.15,16 Although animal studies have shown
that EC seeding increases graft patency rates, similar
studies in humans have not shown a benefit.17 The
major problem encountered is that ECs adhere
poorly to some prosthetic graft materials and are eas-
ily stripped when exposed to flowing blood. Another
problem is that the implantation process in the oper-
ating room exposes the cells to room temperature
and to dehydration during the time it takes to con-
struct the anastomoses.
Stent grafting offers a way to rapidly deliver a
genetically engineered conduit into the circulation.
There are balloon expandable and self-expandable bal-
loon stent grafts available. As mentioned previously,
balloon expansion was traumatic to the seeded cells. In
addition, during balloon deflation, cells sticking to the
balloon are pulled off of the stent graft. Cells on the
exterior of the graft may survive in greater numbers
than those on the graft lumenal surface. Conversely,
cells suffused onto self-expanding stent grafts will like-
ly be stripped off of the exterior surface in large num-
bers as the graft is pushed first into and then out of the
introducer sheath. Cells suffused into the interstices of
either graft type may have a better chance to survive.
Another consideration is the type of configura-
tion of stent graft to use when introducing the cells.
One alternative is to have the stent graft at its maxi-
mal diameter as the cells are suffused into the graft.
The benefit is that a large graft surface area then is
available for cell proliferation and migration. A dis-
advantage is the significant trauma exerted to the
external surface of the stent graft as it is compressed
into an introducer sheath many times smaller in
diameter. Suffusion of the graft at its smallest diam-
eter is feasible with expandable balloon stents.
Suffusion of a self-expandable stent graft at its small-
est (predeployment) diameter may best be per-
formed within the deployment sheath.
In our first application of this technology, we
chose to use a low-profile graft mounted on a bal-
loon expandable stent. Dacron graft and PTFE graft
materials are widely available. Polyurethane carbon-
ate (PUC) is not used clinically because of deterio-
ration of the material over time. However, it offers
the advantages of its low profile and the fact that
cells can easily reside and grow into the PUC matrix.
Unlike Dacron grafts, the material does not have to
be folded on itself to be threaded into the introduc-
er sheath. We found that PUC functioned more like
a true scaffold than did PTFE. We chose to suffuse
these balloon expandable PUC stent grafts in the
unexpanded state to avoid the trauma of having to
compress the grafts to fit into an introducer sheath.
Although balloon expansion into the artery dramat-
ically increases the surface area of the graft, we
hoped to see cells surviving the deployment process
proliferate and cover this area. The application of
this technology to Dacron and PTFE grafts is our
next step.
Not only was survival of the genetically engi-
neered cells observed in our 1-week implants, but
proliferation onto most of the graft surface and even
into the underlying artery intima also was seen.
Although cell survival was evident in our animals at 1
month, a neointima had completely covered the graft
surface. This neointima did not seem to originate
from the cells on the graft, because the X-gal staining
results did not induce a blue nuclear stain in its cells
as it did to the cells immediately adjacent to the stent
graft. These neointimal cells were identified as SMCs
with immunohistochemical staining and may have
originated from either the underlying artery, the
artery at the ends of the stent graft, or both.
The deployment of a stent produces an intimal
injury that incites myointimal hyperplasia.18-20
Prosthetic grafts develop a neointimal lining.
Conferring biologic activity to a stent graft may alter
this lining. One of the major stimuli for neointima
formation is the release of mitogens by platelets
aggregating on the graft surface. Occurring parallel
to this is the stimulus to the clotting cascade, which
ends in the securing of these platelets into a fibrin
mesh. If one were able to alter the kinetics of this
process, for instance by imparting fibrinolytic prop-
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erties to the graft, one may be able to affect the evo-
lution of the neointima.
Gene transfer to overexpress thrombolytic en-
zymes has been reported to enhance the antithrom-
botic activity of vascular ECs and SMCs.21-25 Tissue
plasminogen activator (tPA), a thrombolytic pro-
teinase, can be overexpressed by ECs and SMCs after
intracellular transfer of the tPA gene.25,26
The seeding of cells that are genetically engi-
neered to overexpress tPA onto prosthetic bypass
grafts has been reported by several groups to
improve long-term graft patency rates.26-29 On the
basis of a similar theory, Dichek et al21 have used
such ECs to cover a steel stent that then was balloon
expanded into blood vessels.30,31 A frequent obser-
vation by these investigators is the poor retention of
these cells after exposure to flowing blood in vivo.
One reason for this, in addition to the surface shear
stress, is the protease activity of the up-regulated tPA
on the matrix that would normally secure the cells to
the graft surface.
The suffusion of genetically engineered cells that
secrete a thrombolytic enzyme into the stent graft
scaffolding may favorably impact the evolution of the
neointima by altering the kinetics of fibrin cross link-
ing. Hopefully, the graft membrane will provide a
scaffold and a sanctuary within which the genetically
engineered cells could proliferate while at the same
time preventing the cells from being stripped away by
the shear stress of the overlying flowing blood.
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Dr Gregorio Sicard (St Louis, Mo). Where do we go
from here? I think obviously you are trying to eventually
develop a graft like you said in the beginning, where you
can attach these cells to be used in a commercial fashion.
Dr Darwin Eton. Presently, we are transferring the tis-
sue plasminogen activator (TPA) gene with VSVG–MuLV.
We have achieved a high delivery of the TPA gene into our
cells, equivalent to the rate the lac Z gene reported in this
talk. As a result of the high gene-transfer efficiency, we are
simplifying the gene construct by removing the selection
component of the genome. We may improve gene transfer
efficiency by doing this. We have the following concerns:
(1) TPA is a protease that can digest the extracellular matrix
as it is being excreted, causing the engineered cells to fall off
the graft during flow: we are studying a zymogen of TPA
that will not be active until it contacts the clot; and (2) as
TPA expression is up-regulated, PAI-1, its natural inhibitor
also becomes up-regulated: we are studying a mutant form
of TPA that is resistant to inactivation by PAI-1.
We are now investigating Dacron and polytetrafluo-
roethylene as graft materials. We can suffuse Dacron grafts
at high densities with cells. There are also some other graft
configurations that we are studying. For example, a coax-
ial graft in which the inner prosthetic membrane is semi-
permeable has been made in our laboratory. This mem-
brane allows the gene product to filter out into the circu-
lation while protecting the cells from the shear stress of
flowing blood, and, hypothetically, from cellular immune
response. The latter property may be helpful to permit the
use of allogenic tissue.
Dr Jon Matsumura (Chicago, Ill). I congratulate you
on an immense amount of work, which was no doubt
expensive, given the type of equipment that is necessary
for these animal experiments. You answered a couple of
my questions just now about the choice of TPA and its
possible effect on cell adherence. Could you clarify
whether these are cells that you are showing on only the
inside lumen of the graft or whether they are both on the
inside and on the outside of the graft?
Also, what is the longest period to which you have
taken these VSV transduced cells? I am curious in terms of
the durability of the expression and whether the untrans-
duced subpopulation of cells could overcome the trans-
duced cells.
The last question is, have you looked at any of the dis-
tal sites to see if your cells are moving to other places in
the body?
Dr Eton. We are suffusing cells on the inside, on the
outside, and in the membrane. These cells also grow into
the underlying artery. Balloon deployment trauma (during
inflation and deflation) is of concern. We have been rely-
ing on the remaining cells to repopulate the graft.
Stability data up to 35 days in vitro showed continued
expression of a stable level of TPA. We recently complet-
ed a 2-month experiment in vivo in a pig showing lac Z
gene expression. A thick neointima covers these cells by
that time. Perhaps when we do this experiment with TPA,
we will favorably alter the kinetics of the neointima for-
mation.
Dr Charles Holden (Columbus, Ohio). Again, this is
a remarkable bit of work. I am just curious, have you been
able to assay the TPA that is elaborated by these cells,
either in vitro or otherwise? And have you determined the
duration to which they will continue to express that TPA?
Dr Eton. We have not published our TPA data yet
because this research is in progress. In vitro, the TPA
expression is stable. In vivo, the way that we determine
the TPA activity is to culture the explanted graft and test
for antigen presence and activity using enzyme-linked
immunosorbent assay. As we mentioned, we are attacking
the problem of PAI-1 up-regulation with a mutant form
of TPA.
DISCUSSION
